GH RESEARCH PLC

GHRSNASDAQ

🏆 #1646 by market capEarnings Nov 5US Equity

$29.08▼ $0.44 (−1.52%)

🌙 After hours$29.70▲ 2.13%Regular close · extended-hours price shown

1h—

24h▼ 1.5%

7d▼ 0.3%

14d▲ 4.1%

30d▲ 13.6%

1y▲ 139.7%

🏦Market Cap

$1.99B

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $28.81 – $29.33
52-Week Range: $11.80 – $31.44
Volume: $3.27B
Avg Volume: $3.42B
Shares Outstanding: 68.6M
Next Earnings: Sep 23, 2026

Fundamentals Snapshot

Annual Revenue: $128M
Last Q Revenue: $32M
P/E Ratio: -29.1
P/S Ratio: 0.0x
EPS (TTM): $-0.94
Dividend Yield: 0.00%

Why Investors Own GHRS

✓High-growth profile — revenue up -7.3% YoY with expanding US Equity exposure.
✓Healthy economics — 65% gross margin and 22% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$128M▼ −2.8% YoY

Gross Margin (TTM)

64.9%▲ +3.3% YoY

Operating Income (TTM)

$15M▼ −2.8% YoY

Free Cash Flow (TTM)

$28M▼ −2.8% YoY

About GH RESEARCH PLC

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.

🦦